Connect with us
JPMorgan Chase reduced its stake in Grifols to 3.111%, down from a previous 3.458%, with 0.256% in voting rights and 2.855% through financial instruments. This follows...
Grifols is a listed Catalan pharmaceutical company. The company's activity focuses on the research, development, manufacturing, and marketing of products derived from plasma (blood products), intravenous therapy...
Grifols will reduce the workforce of its industrial plasma business in the United States, its core business, affecting 2,000 workers by 2023. In addition, in corporate...
Grifols closed 2021 with a profit of $192 million (€182.3 million), compared with the $651 million (€618.5 million) recorded in 2020. Grifols recorded a turnover of...